Odyssey Therapeutics, Inc. (ODTX)
NASDAQ: ODTX · Real-Time Price · USD
19.53
-0.01 (-0.05%)
Nov 2, 2026, 4:00 PM EST - Market closed
Odyssey Therapeutics Revenue
Odyssey Therapeutics had revenue of $99.00K in the twelve months ending June 30, 2026, down -96.70% year-over-year. In the year 2025, Odyssey Therapeutics had annual revenue of $2.98M, down -33.45%. That makes Odyssey Therapeutics the 46,096th largest company in the world by revenue and 6,808th in the United States.
Revenue (ttm)
$99.00K
Revenue Growth
-96.70%
P/S Ratio
9,453.01
Revenue / Employee
$990
Employees
100
Market Cap
935.85M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.98M | -1.50M | -33.45% |
| Dec 31, 2024 | 4.47M | 3.44M | 331.24% |
| Dec 31, 2023 | 1.04M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
ODTX News
- 13 days ago - Odyssey Therapeutics Transcript: Investor update - Transcripts
- 13 days ago - Odyssey Therapeutics Press release: Investor update - Filings
- 13 days ago - Odyssey Therapeutics Slides: Investor update - Filings
- 13 days ago - Odyssey Therapeutics reports OD-001 trial meets primary endpoint - TheFly
- 13 days ago - Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026 - GlobeNewsWire
- 21 days ago - Odyssey Therapeutics initiated with a Buy at UBS - TheFly
- 25 days ago - Odyssey Therapeutics initiated with an Outperform at Raymond James - TheFly
- 27 days ago - Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026 - GlobeNewsWire